Payment overview · 2025
General Payments
$207.89
11 reported records · 8 companies
Healthcare provider profile · identity verified
Jontu Solomon, MD
Allopathic & Osteopathic Physicians|Family Medicine · AUGUSTA, GA · NPI 1740701887
Verified facts
What the public records show
CMS Open Payments records show Jontu Solomon, MD received $207.89 in general payments during 2025 across 11 reported records.
Lilly USA, LLC accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.15 | 17.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.56 | 16.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.45 | 16.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.11 | 11.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.42 | 11.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.19 | 11.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.38 | 7.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.63 | 7.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $207.89 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.15 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.56 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.56 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.45 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.45 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.11 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.19 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 101 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 167 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 28 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
101 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
101 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
167 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 578 | 178 |
| Amlodipine Besylate | Amlodipine Besylate | 489 | 136 |
| Losartan Potassium | Losartan Potassium | 369 | 102 |
| Hydrochlorothiazide | Hydrochlorothiazide | 335 | 86 |
| Gabapentin | Gabapentin | 306 | 81 |
| Metformin Hcl | Metformin Hcl | 256 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 229 | 57 |
| Furosemide | Furosemide | 225 | 68 |
| Lisinopril | Lisinopril | 224 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 210 | 54 |
| Potassium Chloride | Potassium Chloride | 198 | 57 |
| Omeprazole | Omeprazole | 190 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 60 |
| Ozempic | Semaglutide | 167 | 30 |
| Simvastatin | Simvastatin | 132 | 34 |
| Carvedilol | Carvedilol | 131 | 36 |
| Trazodone Hcl | Trazodone Hcl | 130 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 127 | 32 |
| Tramadol Hcl | Tramadol Hcl | 120 | 39 |
| Prednisone | Prednisone | 112 | 62 |
| Montelukast Sodium | Montelukast Sodium | 109 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 28 |
| Glimepiride | Glimepiride | 101 | 27 |
| Jardiance | Empagliflozin | 101 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 101 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 28 |
| Naproxen | Naproxen | 98 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 96 | 29 |
| Famotidine | Famotidine | 95 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 37 |
| Meloxicam | Meloxicam | 86 | 18 |
| Allopurinol | Allopurinol | 80 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 79 | 18 |
| Pregabalin | Pregabalin | 79 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 18 |
| Eliquis | Apixaban | 74 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 18 |
| Metformin Hcl Er | Metformin Hcl | 71 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 69 | 58 |
| Clonazepam | Clonazepam | 69 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 26 |
| Alprazolam | Alprazolam | 61 | suppressed |
| Atenolol | Atenolol | 60 | 16 |
| Sertraline Hcl | Sertraline Hcl | 60 | 17 |
| Azithromycin | Azithromycin | 57 | 48 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 54 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 11 |
| Ezetimibe | Ezetimibe | 53 | 21 |
| Finasteride | Finasteride | 50 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 15 |
| Levetiracetam | Levetiracetam | 44 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Fluconazole | Fluconazole | 39 | 25 |
| Meclizine Hcl | Meclizine Hcl | 38 | 14 |
| Ondansetron Odt | Ondansetron | 38 | 18 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 11 |
| Ibuprofen | Ibuprofen | 34 | 14 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 33 | 12 |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Glipizide Er | Glipizide | 31 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 11 |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | 20 |
| Spironolactone | Spironolactone | 29 | 11 |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Rybelsus | Semaglutide | 28 | 12 |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 21 |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | 12 |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Nystatin | Nystatin | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Cefdinir | Cefdinir | 22 | 19 |
| Glipizide | Glipizide | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Mitigare | Colchicine | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Dapsone | Dapsone | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $207.89 · 11 records | Lilly USA, LLC | BREZTRI, Dexcom G6 Transmitter, JARDIANCE, Kerendia, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error